Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA
Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )
1 Jun 2026

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC

Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA
177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC ( Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA )
1 Jun 2026

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma

Dr Marlana Orloff - Thomas Jefferson University Hospital, Philadelphia, USA
Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma ( Dr Marlana Orloff - Thomas Jefferson University Hospital, Philadelphia, USA )
1 Jun 2026

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps

Dr Jessica Paulus - Ontada, Boston, USA
Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps ( Dr Jessica Paulus - Ontada, Boston, USA )
1 Jun 2026

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC

Dr David Pook - Monash Health, Melbourne, Australia
Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC ( Dr David Pook - Monash Health, Melbourne, Australia )
1 Jun 2026

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC

Dr Giannis Mountzios - The University of Athens, Athens, Greece
Tarlatamab improves brain metastases control and survival compared to chemo in SCLC ( Dr Giannis Mountzios - The University of Athens, Athens, Greece )
1 Jun 2026

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada
miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )
31 May 2026

Implanted tile-based radiation shows promise compared with stereotactic radiotherapy for brain metastases

Dr Jeffrey Weinberg - MD Anderson Cancer Center, Houston, USA
Implanted tile-based radiation shows promise compared with stereotactic radiotherapy for brain metastases ( Dr Jeffrey Weinberg - MD Anderson Cancer Center, Houston, USA )
31 May 2026

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC

Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )
31 May 2026

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke
ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )
30 May 2026

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer

Dr Hope Rugo - City of Hope, Duarte, USA
Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer ( Dr Hope Rugo - City of Hope, Duarte, USA )
30 May 2026

ASCO 2026: Breast cancer overview

Dr Hope Rugo - City of Hope, Duarte, USA
ASCO 2026: Breast cancer overview ( Dr Hope Rugo - City of Hope, Duarte, USA )
30 May 2026